Last reviewed · How we verify
Remimazolam infusion
Remimazolam infusion, marketed by Konkuk University Medical Center, is a benzodiazepine currently available in the market. The key composition patent expires in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Remimazolam infusion |
|---|---|
| Also known as | Byfavo |
| Sponsor | Konkuk University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- Effect of Remimazolam on Postoperative Delirium (NA)
- Remimazolam Consumption: TCI vs. Manual Infusion (NA)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial. (NA)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remimazolam infusion CI brief — competitive landscape report
- Remimazolam infusion updates RSS · CI watch RSS
- Konkuk University Medical Center portfolio CI